DUBLIN, Ireland, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced that Dr. Mark Heffernan, Nexvet's Chief Executive Officer, is scheduled to present at the 27th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, December 2nd, at 2:30PM ET.
Dr. Heffernan will provide an overview of Nexvet's pioneering developments in the field of companion animal biologic therapies, including 100% species-specific monoclonal antibody therapies for chronic conditions.
The presentation will be available on the investor section of Nexvet's website at http://ir.nexvet.com for 30 days following the completion of the event.
About Nexvet (www.nexvet.com)
Nexvet is a veterinary biologics developer focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet's proprietary PETization™ platform is designed to rapidly design monoclonal antibodies ("mAbs") that are recognized as "self" or "native" by an animal's immune system, a property Nexvet refers to as "100% species-specificity." Nexvet's product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.
Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, clinical development in the United States and Europe and is growing its biomanufacturing capabilities in Ireland.
CONTACT: Further information: Investors Candice Knoll Blueprint Life Science Group +1 415-375-3340 Ext. 4 email@example.com Media David Salisbury Berry & Company Public Relations +1 212-253-8881 firstname.lastname@example.org
Source:Nexvet Biopharma plc